Zepbound dosage, charted

Each step on the ladder requires a minimum of 4 weeks on the prior dose before increasing — that's a floor, not a target. Your prescriber can, and often does, hold you at a given dose for longer than 4 weeks if side effects haven't settled or if the current dose is already delivering the weight-loss response you're looking for. There's no clinical requirement to move up on schedule the moment 4 weeks passes; the label sets a minimum spacing, not a mandatory pace.

Many people stay long-term at 5mg, 7.5mg, or 10mg if it's delivering steady, tolerable weight loss — reaching 15mg isn't required, and Lilly's own trial data shows meaningful weight loss occurs across the full dose range, not just at the top. Zepbound and Mounjaro use the identical titration schedule and the identical molecule, tirzepatide; the difference between the two products is the FDA-approved indication they're marketed for (weight management versus type 2 diabetes), not the dose or the drug itself.

The 2.5mg starter dose is worth understanding on its own terms: it's specifically sized to let your gastrointestinal system adjust to the drug's effect on gastric emptying, rather than to produce meaningful weight loss on its own. Most people see only modest change during these first four weeks, and that's expected — the dose is functioning as intended, as an adjustment period, not an underperforming treatment.

This isn't a formal clinical classification — it's a pattern drawn from how the titration schedule is designed and how tirzepatide's dose-response relationship generally behaves — but it's a useful frame for setting expectations. The 2.5mg starter dose is rarely where people notice substantial appetite change; most of the early experience is gastrointestinal adjustment: nausea, occasional constipation or diarrhea, and a sense of fullness that arrives sooner during meals.

By 5mg, most people report the first clearly noticeable reduction in appetite and food noise — the mental preoccupation with eating that many describe as quieting down. This is also where side effects, if they're going to be a limiting factor, tend to become most apparent, since it's the first dose delivering a substantial pharmacological effect beyond adjustment.

7.5mg and 10mg are where a large share of people on Zepbound ultimately settle for maintenance, according to real-world prescribing patterns and the trial data underlying the drug's approval — not because higher doses don't work, but because this range often delivers a favorable balance of effect and tolerability for many people. 12.5mg and 15mg exist for people who need more effect and who tolerate the GI side effect profile well enough to continue climbing; they are not a default destination.

Every strength is dosed once weekly, on the same day each week, with or without food, and at roughly the same time of day for consistency — though the label allows some flexibility in timing as long as at least 3 days (72 hours) separate consecutive doses. The vial route, which requires drawing the dose up with a separate syringe, is how LillyDirect delivers its discounted self-pay pricing; the KwikPen auto-injector needs no drawing up and is generally the pricier but more convenient option through standard insurance-covered pharmacy channels.

Each pen or vial is single-dose and single-patient-use — they're not designed to be reused or shared across multiple injections, and each one is discarded after a single administration regardless of whether the full 0.5 mL was used. This differs from some other injectable medications that come in multi-dose vials, and it's a detail worth knowing before assuming leftover volume in a pen can be saved for a future dose.

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the most commonly reported side effects across the titration range, and they tend to cluster around dose increases rather than remaining constant — meaning the first week or two after moving up a step is usually when symptoms are most noticeable, with some settling as your body adjusts to the new dose before the next scheduled increase.

If a step doesn't agree with you, the label explicitly supports staying at your current dose longer than the minimum 4 weeks rather than pushing forward on schedule. Your prescriber can hold you at a lower step for as long as needed, and in some cases can step back down to a previously tolerated dose if side effects at a new step are more than manageable. This is a normal, anticipated part of care with this drug class — it isn't a sign that Zepbound "isn't working" or that you need to stop altogether.

Severe or persistent vomiting, signs of dehydration, or severe abdominal pain (which can, rarely, signal pancreatitis) are reasons to contact your prescriber promptly rather than waiting out the symptom — these are distinct from the common, usually self-limiting GI adjustment most people experience during titration.

If you miss a dose while titrating, the same 96-hour (4-day) catch-up rule applies as it does at any point on Zepbound: take the missed dose as soon as possible within 4 days, then resume your regular weekly schedule. Past 96 hours, skip the missed dose entirely and wait for your next scheduled day — never take two doses within 72 hours of each other to make up for lost time.

A missed dose during active titration doesn't reset your progress up the ladder, but it can shift your schedule for the next planned increase by a day or two if a late catch-up dose pushes the following week's dose out to maintain the 72-hour spacing rule. If you miss more than one dose in a row during titration, it's worth checking in with your prescriber — depending on how long you've gone without a dose, they may recommend restarting at a lower step rather than resuming where you left off, since GI tolerance built up during titration can diminish after an extended gap.

Because Zepbound and Mounjaro are both brand names for tirzepatide, made by the same manufacturer, the titration ladder is identical between them — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg, in the same 4-week minimum steps. What differs is the approved indication printed on each label: Zepbound is approved for chronic weight management (with or without an obesity-related condition) and, separately, for moderate-to-severe obstructive sleep apnea with obesity; Mounjaro is approved for type 2 diabetes. Insurers frequently use this labeling distinction, not the dose itself, to determine which product they'll cover for which diagnosis — meaning your titration experience is pharmacologically the same regardless of which bottle or pen box you're handed, but your insurance coverage path can differ significantly.

This also explains why some people are prescribed Mounjaro "off-label" for weight loss when their insurance won't cover Zepbound, or vice versa in diabetes cases — the drug and dosing math travel with the molecule, not the brand name.

The 4-week minimum is a floor set by the label, but real-world prescribing frequently moves slower, especially for people who experience noticeable GI side effects at a given step. It's common for prescribers to extend a dose an extra 2–4 weeks beyond the minimum if nausea, vomiting, or diarrhea haven't settled, rather than advancing on the earliest possible date. Neither approach is "correct" in isolation — the schedule is a maximum pace, not a target pace, and slower titration doesn't reduce the medication's eventual effectiveness at a given maintenance dose.

Some people also plateau in weight loss at a given dose for a period of weeks before it resumes — this is a normal, well-documented pattern with GLP-1 and dual-agonist therapies generally, and on its own isn't a signal that a dose increase is necessary. Discussing the pattern with your prescriber, rather than assuming a stall means "time to go up," is the more reliable way to decide on the next step.

It's worth reading the phrase "4-week minimum" the way it's actually written in Zepbound's FDA-approved prescribing information: it names the shortest interval allowed before advancing to the next dose, not a required or recommended interval. Taken literally, the label sets a floor with no corresponding ceiling — a prescriber could leave a patient at 5mg for six months or longer if that's clinically appropriate, and doing so would be entirely consistent with the approved labeling, not a deviation from it. Nothing in the label specifies a maximum amount of time a patient may remain at any given step, which is a large part of why real-world titration paces vary so widely between individual patients even though everyone is nominally following "the same" FDA-approved schedule.

Because Zepbound is dosed once weekly rather than daily, it tolerates travel and schedule disruption better than many medications, but titration adds a layer of planning worth thinking through before a trip. The rule that governs everyday timing — at least 72 hours between consecutive doses — is the same rule that governs travel-related shifts. If a trip crosses time zones or disrupts your usual injection day, you can generally move your dose earlier or later within that window without affecting your position on the titration ladder, as long as two doses don't end up closer together than 3 days apart.

The finer edge cases are where planning matters more. If a scheduled dose increase happens to land in the middle of a trip, many people choose to finish the trip on their current, already-tolerated dose and start the higher step once they're back to a predictable routine — deliberately delaying past the 4-week minimum for this reason is explicitly permitted by the label, and travel is a common, reasonable justification to do it. Starting a new, higher dose for the first time away from home, particularly on a multi-day trip with limited control over food or bathroom access, is something many prescribers actively steer patients away from, since the days right after a step-up are when GI side effects are most likely to show up.

Packing also means accounting for temperature: unused Zepbound pens and vials need to stay refrigerated until first use, though current labeling allows a limited window of room-temperature storage once a pen is in active use. An insulated travel case with an ice pack is worth the extra bag space on any multi-day trip, especially in hot climates or if the pen might end up in checked luggage that sits on a tarmac for an unknown stretch of time.

The 15mg maximum dose isn't a finish line everyone is meant to reach — it's the ceiling of the approved range, reserved for the subset of people whose response plateaus at a lower dose and who are both tolerating treatment well and interested in pursuing additional effect. In Lilly's SURMOUNT trials supporting Zepbound's approval, participants at every studied dose — including 5mg and 10mg, not just the top of the range — showed clinically meaningful average weight loss, which is part of why 15mg isn't a default target the way a "go as high as possible" framing might suggest.

In practice, the decision to keep climbing usually comes down to three questions considered together, rather than any single one in isolation: is the current dose still tolerable, is progress still meaningful at the current dose, and has enough time actually passed at the current step to know the answer rather than guessing early. A dose that's still producing steady loss alongside mild, manageable side effects is often left alone rather than pushed higher for its own sake. A dose where progress has genuinely stalled for a period of weeks, and where side effects remain minor, is the more typical candidate for a step up.

Stopping the climb early is equally appropriate when side effects at a given step are borderline tolerable — nausea that's frequent but not severe, for example — since going higher tends to intensify the same GI effects rather than introduce new ones. There's no clinical penalty for staying at 7.5mg or 10mg indefinitely if that's where the balance of effect and tolerability lands for you. Long-term maintenance at a mid-range dose is a common, fully supported outcome of titration, not a compromise or a sign the medication "didn't work as well" as it should have.

Tirzepatide's step-up philosophy — start low, hold for a set minimum, climb in fixed increments toward a ceiling — isn't unique to Zepbound; it's the standard approach across the GLP-1 and dual-agonist class, though the specific pace and increments differ by drug. Semaglutide, sold as Wegovy for weight management and Ozempic for type 2 diabetes, follows a broadly similar 4-week-per-step cadence, moving through 0.25mg, 0.5mg, 1mg, and 1.7mg on the way to a 2.4mg maintenance dose for Wegovy (a higher 7.2mg step was added to the Wegovy label in 2026, for people who need more effect after at least 4 weeks at 2.4mg). Ozempic's diabetes-focused ladder tops out lower, at 2mg.

Liraglutide, sold as Saxenda for weight management, takes a notably faster approach: instead of a 4-week minimum per step, its label calls for weekly increases — 0.6mg, 1.2mg, 1.8mg, 2.4mg, then 3mg — reaching maintenance dose in about five weeks rather than the four-to-five months Zepbound's full ladder can take. That faster pace is one reason liraglutide requires daily rather than weekly injections, and it tends to produce a more front-loaded GI adjustment period; the slower, weekly-injection titration used by Zepbound and Wegovy generally trades a longer runway for gentler week-to-week side effects.

None of these schedules are interchangeable, and switching between drug classes isn't as simple as matching a "dose number" from one to another. A prescriber moving someone from one GLP-1 or dual-agonist medication to a different one typically restarts titration from that new drug's own starting dose, rather than translating upward from wherever the previous medication left off, since the drugs aren't dosed on an equivalent mg-for-mg basis.